The Role of a Clinical Pharmacist in Lifestyle Modification in Type 2 Diabetic Patients With Peripheral Neuropathy

Not Applicable

• Conditions: Diabetic Peripheral Neuropathy

• Registration Number: NCT03356041
• Lead Sponsor: Hawler Medical University

Brief Summary

The aims of this study are to determine the prevalence of diabetic peripheral neuropathy among the diabetic patients, to determine the association between the clinical profiles of the diabetic patients (diabetes type, diabetes duration, HbA1c, body mass index, hypertension, total cholesterol) and the diabetic peripheral neuropathy DPN and the rational poly pharmacy used to control pain.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-11
• Study First Submitted: 2017-11-17
• Study First Submitted QC: 2017-11-22
• Last Update Submitted: 2017-11-22
• Study First Posted: 2017-11-29
• Last Update Posted: 2017-11-29
• Study Start: 2017-12-20
• Primary Completion: 2018-03-16
• Study Completion: 2018-03-23

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

1. History of alcohol consumption.

2. Thyroid gland disorder.

3. Any kidney disorder.

4. Any conditions that could confound assessment of pain due to diabetic peripheral neuropathy.

5. Have foot injury or open sore.

6. Pregnant females or who plan to become pregnant during the study period.

7. Any serious medical condition that might prevent completion or hinder compliance with exercise.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Estimating Summary of diabetes self-care activity (SDSCA)	Three months	Assessing Lifestyle modification by summary of diabetes self-care activity (SDSCA) at baseline visit and after three months for both Intervention patients and usual care group Increases in the means of the items of the scale as Exercise, Blood sugar testing, Specific diet and Foot care in the intervention group.
Adherence to treatment according to Morisky scale	Three months	Morisky scale is used to assess medication adherence at baseline visit and after three months for both Intervention patients and usual care group.; Improving the patient medication adherence behavior in the intervention group patients
Douleur Neuropathique 4 (DN4), Neuropathic Pain Scale (NPS),	Three months	Reduction in the percent of response of patients feeling; electric shock, tingling, and pin needle after the lifestyle modification in the intervention group.

Trial Locations

Locations (1)

Prof. Kawa Dizaye; 🇮🇶 Erbil, Iraq